A61K 40/4213
Cd74, ii, mhc class ii invariant chain or mhc class ii gamma
Official title: {CD74, Ii, MHC class II invariant chain or MHC class II gamma chain}
A61K40/4213 (Cd74, ii, mhc class ii invariant chain or mhc class ii gamma) appears on 19 US grants and 52 published applications in this corpus.
Search patents in A61K- Granted patents
- 19
- Published applications
- 52
- Assignees
- 31
- Inventors
- 140
- Latest grant
- 17 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 1 | 3 |
| 2019 | 0 | 6 |
| 2020 | 3 | 2 |
| 2021 | 7 | 8 |
| 2022 | 3 | 1 |
| 2023 | 1 | 6 |
| 2024 | 0 | 7 |
| 2025 | 1 | 8 |
| 2026 | 1 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Teleost invariant chain cancer vaccine17 Mar 2026US 12,576,143 B2Nouscom AG
- Proteolytically cleavable chimeric polypeptides and methods of use thereof15 Jul 2025US 12,358,988 B2The Regents of the University of California
- Materials and methods for engineering cells and uses thereof in immuno-oncology11 Apr 2023US 11,622,977 B2Crispr Therapeutics AG
- Materials and methods for engineering cells and uses thereof in immuno-oncology18 Oct 2022US 11,471,491 B1Crispr Therapeutics AG
- Proteolytically cleavable chimeric polypeptides and methods of use thereof2 Aug 2022US 11,401,332 B2The Regents of the University of California
- Cd74 car-t therapy and methods of use thereof3 Sep 2026US 2026/0256912 A1Ohio State Innovation Foundation
- Ccr9 targeting moiety for the treatment of ccr9-positive cancer13 Aug 2026US 2026/0232732 A1
- Method for selectively inducing antigen-specific inductive regulatory t cells6 Aug 2026US 2026/0224622 A1Junten Bio Co., Ltd.
- Antibody against blood cancer25 Jun 2026US 2026/0174798 A1The University of Osaka
- Nanoparticles for delivery of immunoregulatory materials to t cells14 May 2026US 2026/0130992 A1The Johns Hopkins University
Most cited
By later US patents
- Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells33US 4,861,589 ATrustees of Boston University · 1989
- Materials and methods for engineering cells and uses thereof in immuno-oncology14US 10,736,919 B2Crispr Therapeutics AG · 2020
- Constructs targeting AFP peptide/MHC complexes and uses thereof12US 10,011,658 B2Eureka Therapeutics, Inc. · 2018
- Materials and methods for engineering cells and uses thereof in immuno-oncology11US 10,857,184 B2Crispr Therapeutics AG · 2020
- Materials and methods for engineering cells and uses thereof in immuno-oncology9US 10,729,725 B2Crispr Therapeutics AG · 2020